Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
- Company previously disclosed settlement agreement in principle and fully provisioned for this resolution
Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying conduct. Today’s settlement contains no new factual allegations against Sandoz, and the company fully provisioned for this settlement and disclosed the agreement in principle as part of the March 2020 resolution.
As recognized by the DOJ, Sandoz cooperated with the government’s investigation. The conduct at issue here occurred at Sandoz from March 2013 through December 2015 in direct contravention of the company’s values, policies and trainings in place at the time. The individuals implicated in the underlying conduct are no longer employed by the company.
As part of the agreement, Sandoz will pay USD 185 million, plus interest from the date of the agreement in principle to settle, and has agreed to corporate integrity obligations with the Office of Inspector General of the U.S. Department of Health and Human Services through 2026.
Keren Haruvi, President of Sandoz Inc., said: “Today’s settlement bookends the March 2020 resolution and resolves all outstanding federal government matters concerning the DOJ’s investigation into our historical conduct. The agreement is consistent with our commitment to resolve legacy compliance matters and continuously improve our compliance and training programs and evolve our controls. We’re moving forward and remain focused on pioneering new ways to help people around the world access high-quality medicines.”
Since the time of the referenced conduct, Sandoz has further evolved its compliance program in the spirit of continuous improvement. Given that this resolution includes a Corporate Integrity Agreement, Sandoz will be implementing controls designed to ensure compliance with the terms of this settlement. Sandoz strives to operate at the highest levels of sound governance as it reinforces its global leadership in generic pharmaceuticals and biosimilars covering all major therapeutic areas.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “expected,” “provisioned,” “will,” “commitment,” “to resolve,” “continuously,” “evolve,” “further evolved,” “implementing,” “strives,” “to operate,” “portfolio,” “purpose,” “ambition,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the generic and biosimilar products described in this press release, or regarding potential future revenues from such products, or regarding the resolution, the settlement agreement, the investigation into the generic pharmaceutical industry, our corporate integrity obligations, and the compliance activities described in this press release. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the ongoing and future enhancements to our compliance activities, including with regards to our corporate integrity obligations, will be successful, or achieve any particular outcome, or in any particular time frame. Neither can there be any guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding the resolution, the settlement agreement, the ongoing and future enhancements to our compliance activities, including with regards to our corporate integrity obligations, and such products could be affected by, among other things, the possibility that our enhanced compliance activities may not successfully prevent or detect all future improper activities; regulatory actions or delays or government action generally; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity, or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.
Sandoz is on Twitter. Sign up to follow @Sandoz global at http://twitter.com/Sandoz_Global
# # #
Novartis and Sandoz Global Communications
E-mail : firstname.lastname@example.org
| Richard Jarvis|
Novartis Global Communications
+41 79 584 23 26 (mobile)
| Chris Lewis|
Sandoz Global Communications
+49 174 244 9501 (mobile)
| Julie Masow|
Novartis US Communications
+1 862 579 8456 (mobile)
| Leslie Pott|
Sandoz US Communications
+1 201 354 0279 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
| Thomas Hungerbuehler |
| +41 61 324 8425|
+41 61 324 7188
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PubMatic and Semasio Expand Partnership and Deliver Increased Reach for Omnicom Media Group20.10.2021 09:00:00 CEST | Press release
By activating Semasio’s audience segments within PubMatic’s Audience Encore, OMD Netherlands and OMG Germany engaged more consumers compared to DSP activation LONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Today, PubMatic, a sell-side platform that delivers superior outcomes for digital advertising, and Semasio, a pioneer in Unified Targeting which seamlessly combines audience and contextual targeting on the buy- and the sell-side, announced an expanded partnership that enables media buyers to increase audience addressability at a user- and page-level. Semasio’s audience and contextual segments can now be activated directly in PubMatic’s sell-side platform (SSP) for rapid, precision targeting. With the prevalence of third-party cookies continuing to decline and consumer privacy paramount, it is important for agencies to re-define audience addressability strategies to optimise reach. A common concern when targeting data segments is the risk of suboptimal reach due to poor cookie match rates.
Nexstim Plc Business and Clinical Update Q3 202120.10.2021 09:00:00 CEST | Press release
Press release,Helsinki, 20 October 2021 at10:00 AM (EEST) Nexstim Plc Business and Clinical Update Q3 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of the Company’s business and clinical progress during Q3 2021. CEO Mikko Karvinen’sBusiness and Clinical Update I’m very happy to inform that following the strongest first half in the history of the company, our operational business has continued to show positive progress during the third quarter of the year. We have continued to focus on the growth of our Diagnostics Business (NBS) and Therapy Business (NBT®) new system sales in both of our key markets in the United States and Europe. At the same time, we have seen interest in our existing NBS and NBT® System customer base for system upgrades and continued to increase the utilisation rate of our installed base to a record level. This has led into steadily growing recurring revenue levels, which creates stability and a new kind of predictabil
Nexstim Abp:s uppdatering om verksamheten och kliniska framstegen tredje kvartalet 202120.10.2021 09:00:00 CEST | Pressemelding
Pressmeddelande, Helsingfors, 20 oktober 2021 kl. 10.00(EEST) Nexstim Abp:s uppdatering om verksamheten och kliniska framstegen tredje kvartalet 2021 Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) redogör för de viktigaste händelserna i bolagets verksamhet och kliniska framsteg tredje kvartalet 2021. Vd Mikko Karvinens synpunkter på affärsverksamheten och kliniska framstegen Det gläder mig att kunna berätta att bolaget efter det starkaste halvåret i dess historia har haft fortsatt positiv tillväxt inom affärsverksamheten under tredje kvartalet. Vi har fortsatt att satsa på att öka försäljningen av nya system inom diagnostikverksamheten (NBS) och terapiverksamheten (NBT®) på bägge två av våra huvudmarknader, nämligen USA och Europa. Samtidigt har befintliga kunder för NBS och NBT® uppvisat ett intresse för systemuppgraderingar, vilket har bidragit till en rekordhög användningsfrekvens av den installerade basen. Som en följd har de återkommande intäkterna ökat, vilket ger
Yara reports improved returns20.10.2021 08:00:00 CEST | Press release
Oslo, 20 October 2021:Yara delivers improved returns reflectinghigher prices in third quarter.Net income was a negative USD 143 million, compared with a positive USD 340 million a year earlier. The negative net income includesa USD 355 million impairment ofSalitre assetsin line with Yara’sregulatory release dated1 August 2021,and a currency translation loss of USD 148 million. Excluding currency effects and special items, the basic earnings per share was USD 1.33 compared with USD 0.88 per share in third quarter 2020. The main elements of the third-quarter results are: Improved returns reflecting higher prices8.3% ROIC1, up from 7.9% a year earlier40% ammonia curtailment in Europe due to natural gas price spike “Yara delivers solid third quarter results, with EBITDA2 excluding special items up 37%, mainly thanks to improved margins. However, the gas price spike in Europe has led to Yara curtailing around 40% of its European ammonia production,” said Svein Tore Holsether, President and
Kinnevik: Interim report 1 January – 30 September 202120.10.2021 08:00:00 CEST | Press release
”We continue to strengthen and build out our growth portfolio at a rapid pace to maintain the momentum of our strategic transformation, and note the interest of founders and investors to partner with us. This is a significant recognition of our ability to identify the businesses of tomorrow and be their preferred investor as they grow and shape a re-imagined everyday.” Georgi Ganev, CEO of Kinnevik Key Strategic Highlights Betterment raised USD 160m in a funding round to accelerate the record growth the company has delivered year-to-date across its B2C and B2B offering, leading to a significant uplift in valuation Cityblock raised additional capital to extend its reach and battle health inequities for a fast-growing member population, at a valuation twice as high as the round in March this yearBabylon reaffirmed its 2021 and 2022 growth guidance and secured USD 200m in sustainability-linked financing as it nears completion of its SPAC merger transaction We strengthened our Growth Portf
ING to offer compensation to Dutch retail customers with certain consumer credit products20.10.2021 08:00:00 CEST | Press release
ING to offer compensation to Dutch retail customers with certain consumer credit products ING announced today to offer a compensation to our Dutch retail customers with certain revolving consumer loans where the variable interest rate did not sufficiently follow market rates. With this step, ING reacts to a number of rulings by the Dutch Institute for Financial Disputes (Kifid) regarding similar products at other banks. We have investigated the relevance of these rulings for our floating-rate credit products in the Netherlands. This is expected to concern approximately 10% of the contracts for these products. The Dutch Consumers’ Association (Consumentenbond) has reacted positively on ING’s intention and is prepared to further discuss the execution and details of the scheme, which is expected to be completed before the end of 2022. ING will book a provision of €180 million in its third quarter 2021 results for the compensation and costs of executing the scheme. More details on the comp
Yara leverer økt avkastning20.10.2021 08:00:00 CEST | Pressemelding
Oslo, 20. oktober 2021:Yara rapporterer økt avkastning i tredje kvartal som følge av høyere priser,Nettoresultatvar negativt USD 143 millionersammenlignet med positivt USD 340 millioner ett år tidligere.Det negative nettoresultatet inkluderer en USD 355 millioner nedskrivning av Salitre-prosjektet med referanse til Yaras børsmelding 1. august 2021, og et valutatap på USD 148 millioner. Nettoresultat eksklusive valutaeffekter og spesielle poster, var USD 1,33 per aksje sammenlignet med USD 0,88 for tredje kvartal 2020. Hovedelementene i resultatet for tredje kvartal er: Økt avkastning som følge av høyere priser8,3 % ROIC1, opp fra 7,9% ett år tidligere40% midlertidig kutt i amoniakkproduksjon i Europa som følge av høy gasspris «Yara leverer et solid resultat for tredje kvartal, med EBITDA1 eksklusive spesielle poster opp 37%, hovedsakelig som følge av økte marginer. Imidlertid har den høye gassprisen i Europa ført til at Yara har midlertidig kuttet ca 40% av sin europeiske ammoniakkprod